Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma

Tissue Antigens

Volumn 71, Issue 2, 2008, Pages 146-150

  Bogunia Kubik, K ^a   Mazur, G ^b   Wrobel T ^b   Kuliczkowski, K ^b   Lange, A ^a,c  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry   (Poland)

Author keywords

Aggressiveness; Course of disease; IL 10 gene polymorphisms; Non Hodgkin's lymphoma; Number of extranodal sites

Indexed keywords

INTERLEUKIN 10; LACTATE DEHYDROGENASE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

FEMALE; GENETIC MARKERS; HUMANS; INTERLEUKIN-10; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS (GENETICS);

EID: 38049161446     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2007.00984.x     Document Type: Article

References (23)

1. Benjamin D, Knobloch TJ, Dayton MA. Human B-cell interleukin 10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 1992: 80: 1289 98.
2. Rousset F, Garcia E, Defrance T et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992: 89: 1890 3.
3. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin 10 and the interleukin receptor. Annu Rev Immunol 2001: 19: 683 765.
4. Turner DM, Williams DM, Sarakan D, Lazarus M, Sinnot PJ, Hutchinson IV. Investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997: 24: 1 8.
5. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998: 95: 9465 70.
6. Rothman N, Skibola CF, Wang SS et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006: 7: 27 38.
7. Purdue MP, Lan Q, Kricker A et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 2007: 28: 704 12.
8. Lech-Maranda E, Baseggio L, Bienvenu J et al. Interluekin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004: 103: 3529 34.
9. Persico M, Capasso M, Persico E et al. Interleukin-10 -1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J Hepatol 2006: 45: 779 85.
10. Breen EC, Boscardin WJ, Detels R et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10 or the IL10 promoter -592 C/C genotype. Clin Immunol 2003: 109: 119 29.
11. Lan Q, Zheng T, Rothman N et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin's lymphoma. Blood 2006: 15: 4101 8.
12. Cunningham LM, Bhapman C, Dunstan R, Bell MC, Joske DJ. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003: 44: 251 5.
13. Lee J-J, Kim DH, Lee NY et al. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol 2007: 137: 329 36.
14. Mazur G, Bogunia-Kubik K, Wrobel T, Kuliczkowski K, Lange A. TGF-beta1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients. Cytokine 2006: 33: 145 9.
15. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999: 42: 1101 8.
16. Eskdale J, Gallagher G. A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics 1995: 42: 444 5.
17. Lim S, Crawley E, Woo P, Barnes P. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 1998: 352: 113.
18. Mazur G, Bogunia-Kubik K, Wrobel T et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 2005: 96: 241 6.
19. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in IFN-γ, interleukin-10, transforming growth factor-β1 and tumour necrosis factor-α genes: a technical report. Transpl Immunol 1998: 6: 193 7.
20. Cervenak L, Morbidelli L, Donati D et al. Abolished angiogenecity and tumorgenecity of Burkitt lymphoma by interleukin-10. Blood 2000: 96: 2568 73.
21. Groux H, Bigler M, de Vries JE, Roncarolo MG Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998: 60: 3188 93.
22. Groux H, Cottrez F, Rouleau M et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen presenting cells. J Immunol 1999: 162: 1723 9.
23. Wanidworanun C, Stober W. Predominant role of tumor necrosis factor - alpha in human monocytes IL-10 synthesis. J Immunol 1993: 151: 6853 61.